Keytruda Improves Survival in Triple-Negative Breast Cancer
Keytruda Improves Survival in Triple-Negative Breast Cancer
September 15, 2024
People diagnosed with early-stage triple-negative breast cancer who received the immunotherapy Keytruda (chemical name: pembrolizumab) along with chemotherapy before and after surgery had better event-free survival — how long they lived without the cancer coming back. Read more…
Comments
-
Hi - my mom (now78) was diagnosed with TNBC the end of last year. She went through 3 rounds of chemo and didn't fair well, developed severe neuropathy, so they stopped. She still has the neuropathy and it might be permanent. She continued the Keytruda for the last 5 months after chemo ended. Since her neuropathy was getting worse, we thought it may be from the Keytruda (a side effect). Have you seen this with patients and is the Keytruda still worth it, for the 5% reduction in reoccurence rate? We're also concerned and with her age, of after treatment auto-immune disorders, how often does this occur? Thank you for your insight and help.
0
